US Bancorp DE Acquires 7,336 Shares of Acelyrin, Inc. (NASDAQ:SLRN)

US Bancorp DE raised its holdings in shares of Acelyrin, Inc. (NASDAQ:SLRN) by 77.1% in the third quarter, Holdings Channel.com reports. The firm owned 16,854 shares of the company’s stock after purchasing an additional 7,336 shares during the period. US Bancorp DE’s holdings in Acelyrin were worth $83,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in SLRN. China Universal Asset Management Co. Ltd. increased its position in Acelyrin by 65.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,196 shares of the company’s stock valued at $95,000 after buying an additional 7,560 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of Acelyrin by 129.6% during the third quarter. SG Americas Securities LLC now owns 26,755 shares of the company’s stock valued at $132,000 after acquiring an additional 15,101 shares in the last quarter. Cubist Systematic Strategies LLC raised its position in shares of Acelyrin by 158.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 90,022 shares of the company’s stock worth $397,000 after purchasing an additional 55,141 shares during the last quarter. Almitas Capital LLC bought a new position in Acelyrin in the 2nd quarter worth about $1,659,000. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in Acelyrin during the 2nd quarter valued at about $706,000. 87.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have issued reports on SLRN shares. Wells Fargo & Company lifted their target price on shares of Acelyrin from $13.00 to $15.00 and gave the stock an “overweight” rating in a report on Wednesday, October 16th. HC Wainwright upped their price objective on Acelyrin from $6.00 to $8.00 and gave the company a “neutral” rating in a research report on Thursday. Morgan Stanley reduced their target price on Acelyrin from $13.00 to $6.00 and set an “equal weight” rating for the company in a report on Monday, August 19th. Finally, Piper Sandler lowered their price target on Acelyrin from $68.00 to $20.00 and set an “overweight” rating on the stock in a report on Wednesday, August 14th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $11.50.

Acelyrin Stock Down 9.1 %

Shares of Acelyrin stock opened at $4.69 on Friday. Acelyrin, Inc. has a twelve month low of $3.36 and a twelve month high of $9.20. The company has a market cap of $468.11 million, a price-to-earnings ratio of -1.91 and a beta of 1.98. The company’s 50 day moving average is $5.41 and its 200 day moving average is $5.02.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.